Otsuka Pharmaceutical Development & Commercialization, Inc.
Clinical trials sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., explained in plain language.
A subsidiary of Otsuka Holdings, focused on developing and commercializing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a Once-Daily pill tame ADHD and emotional storms?
Disease control Not yet recruitingThis trial is testing whether an experimental medication called centanafadine, taken once daily as extended-release capsules, can help adults with attention-deficit/hyperactivity disorder (ADHD) who also experience emotional dysregulation—difficulty managing emotions like irritab…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug HBM7020 tested in humans for first time against autoimmune diseases
Disease control Not yet recruitingThis first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Tiny study tracks experimental schizophrenia Drug's journey in healthy men
Knowledge-focused Not yet recruitingThis early-stage trial will give 8 healthy men a single dose of a radioactive-labeled experimental drug called SEP-380135, which is being developed for schizophrenia. The goal is to track how the drug is absorbed, broken down, and eliminated from the body. This study does not tes…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC